This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
Settings
This website uses cookies and similar technologies to provide the best functionality and display content according to your interests on our site and social networks.

We respect your privacy and process information only for marketing and functional purposes if you give us your consent by clicking ‘I accept.’
You can change your cookie settings at any time by clicking on the privacy settings.

Terms of use
Privacy Notice
This cookie is used for system purposes only and does not track user actions. It is required for normal functioning of this web site.
This is a web analytics service.
Processing company
  • Google Ireland Limited
  • Google Building Gordon House, 4 Barrow St, Dublin, D04 E5W5, Ireland
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
This is a Tracking technology offered by Facebook and used by other Facebook services such as Facebook Custom Audiences.
Processing company
  • Facebook Ireland Limited
  • 4 Grand Canal Square, Grand Canal Harbour, Dublin, D02, Ireland
Data Purposes
  • advertising
  • Marketing
  • Retargeting
  • Analyse
  • Tracking
Technologies Used
  • Cookies
Data Attributes
  • Pixel specific data
  • Http-Header
  • Optional Parameters
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • Facebook user ID
  • Browser information
  • Usage data
  • Geräteinformationen
  • Non-sensitive custom data
  • Referrer URL
  • Pixel ID
  • Location information
  • Pixel specific data
  • User behaviour
  • Ads viewed
  • Interactions with advertisement, services, and products
  • Marketing information
  • Content viewed
  • IP address
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 para. 1 s. 1 lit. a GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Facebook Inc.
This is a web analytics service.
Processing company
  • Zoom Analytics Ltd.
  • Petah Tikva, Israel
Data Purposes
  • Marketing
  • Advertisement
  • Web Analytics
Technologies Used
  • Cookies
  • Pixel Tags
Data Attributes
  • IP address (anonymised)
  • Browser information (browser type, referring/exit pages, the files viewed on our site, operating system, date/time stamp, and/or clickstream data)
  • Usage Data (views, clicks)
Data Collected
This list represents all (personal) data that is collected by or through the use of this service.
  • IP address
  • Date and time of visit
  • Usage data
  • Click path
  • App updates
  • Browser information
  • Device information
  • JavaScript support
  • Pages visited
  • Referrer URL
  • Downloads
  • Flash version
  • Location information
  • Purchase activity
  • Widget interactions
Legal Basis
  • In the following the legal basis for the processing of personal data required by Art. 6 I 1 GDPR is listed.
  • Art. 6 (1) (a) GDPR
Location of Processing
  • Republic of Serbia
Retention Period
  • The data will be deleted as soon as they are no longer needed for the processing purposes.
Data Recipients
  • Alphabet Inc.
Regional Pharmaceutical Leader Marks Its 60th Birthday
01. June 2020.

Hemofarm – A Success Story on Longevity, Records and Patient-Tailored Medicines


Hemofarm, the leading pharmaceutical company in the region, today marks 60 years of continuous growth, numerous business achievements and continuous breaking of own records. Evolving from a small plant, established in Vršac on 1 June 1960, Hemofarm is presently a regional leader operating globally, on three continents and in 36 countries across the world.

At the beginning of its operation back in 1960, Hemofarm had 30 employees, while it currently employs around 3,500 people. Ever since Aminopirin, the first medicine manufactured in Hemofarm’s plants, a precursor to currently produced Midol 100, to date, when the portfolio of this company comprises about 400 products in different forms and doses, the decades of operation have been dedicated to the development of quality, effective and affordable medicinal products.

The company has improved its business operations year in, year out, ending the last year, 2019, with as high as a triple record: in production volume (5.7 billion tablets and other pharmaceutical forms produced in Hemofarm’s plants), in product portfolio size, and in sales. In the year of marking its jubilee, it expects to score a new production record of around seven billion tablets, capsules and other forms.

‘I am proud of the fact that Hemofarm has been constantly evolving, becoming ever more successful, and that there were no oscillations or declines, but only new records in our business history. Our success comes as a product of the synergy of local knowledge and German cutting-edge technology, resulting in world-class pharmaceuticals. The same medicines taken by Serbs are taken by Germans and Russians, too. Patients and the health of citizens are our priority, and we have therefore developed the widest range of medicines in the region, putting disease prevention in the focus of our activities‘, Dr Ronald Seeliger, CEO of Hemofarm, said on the occasion of the jubilee, adding that the significance of this company is reflected in its contribution to improvement of the health of citizens, as well as the health of economy of the country.

Hemofarm is a leader not only in Serbia, but also in Bosnia and Herzegovina and Montenegro. Apart from being Number 1 in these countries, last year Hemofarm Banjaluka and Hemomont in Podgorica scored the highest production output ever since their foundation. ‘Since 2003, when the solid dosage forms plant in Banjaluka was put into operation, Hemofarm has become a leader on the pharmaceutical market of Bosnia and Herzegovina in a very short period of time. We have also established a unique quality system at Hemofarm’s manufacturing sites in Serbia, Bosnia and Herzegovina and Montenegro, which proves that the exchange of knowledge and good practices knows no boundaries’, the CEO of Hemofarm emphasized.

Since 2006, Hemofarm has been a member of STADA Group, one of the leading pharmaceutical companies in Europe, which has invested more than 300 million euros in modernization of plants, equipment and new facilities to date.

In addition to running a successful business, continuous support to the community in which it was founded, was an important earmark of Hemofarm in the previous 60 years. The company donates medical equipment and medicines to hospitals every year, while supporting educational, cultural and other organizations either financially or by providing professional support. It also helps others through Hemofarm Foundation, which has made donations and accomplished the activities worth as much as 13 million EUR so far.

Production output results doubled and tripled in 10 years


Over the course of the last 10 years alone, Hemofarm doubled its production volume in packs, and tripled it in terms of the number of tablets and complexity. For example, 150 million packs, i.e. 2.3 billion tablets and other forms, and 916 different products were manufactured in its plants in 2010. The company will end this year with more than 300 million packs, seven billion tablets and other forms, and more than 3,000 different products.